Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.

@article{Wilson1995PhaseIA,
  title={Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.},
  author={Wyndham H. Wilson and Carlos A. Jamis-Dow and Geoffrey Bryant and Frank M Balis and Raymond W. Klecker and Susan E Bates and Bruce Allan Chabner and Seth Steinberg and David D. R. Kohler and Robert E. Wittes},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1995},
  volume={13 8},
  pages={1985-94}
}
PURPOSE Dexverapamil is a competitive inhibitor of the P-glycoprotein (Pgp) efflux pump, a potent mechanism of multidrug resistance (mdr-1) in vitro. We performed a phase I study to determine the maximum-tolerated dose (MTD) and pharmacokinetics of dexverapamil with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) chemotherapy. PATIENTS AND METHODS Eligible patients had relapsed or refractory lymphoma or sarcoma. Patients initially received EPOCH alone, and those… CONTINUE READING